1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Paroxysmal Nocturnal Hemoglobinuria Market
2.2. Global Paroxysmal Nocturnal Hemoglobinuria Market, By Treatment, 2024 (US$ Million)
2.3. Global Paroxysmal Nocturnal Hemoglobinuria Market, By Geography, 2024 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2024

3. Paroxysmal Nocturnal Hemoglobinuria Market: Competitive Analysis
3.1. Market Positioning of Key Paroxysmal Nocturnal Hemoglobinuria Market Vendors
3.2. Strategies Adopted by Paroxysmal Nocturnal Hemoglobinuria Market Vendors
3.3. Key Industry Strategies

4. Paroxysmal Nocturnal Hemoglobinuria Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Paroxysmal Nocturnal Hemoglobinuria Market Value, 2023 - 2033, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2024 Versus 2033
5.3. Market Segmentation
5.3.1. Blood Transfusion
5.3.2. Medication
5.3.3. Stem Cell Transplant


6. North America Paroxysmal Nocturnal Hemoglobinuria Market, 2023-2033, USD (Million)
6.1. Market Overview
6.2. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
6.3.Paroxysmal Nocturnal Hemoglobinuria Market: By Region, 2023-2033, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)

7. UK and European Union Paroxysmal Nocturnal Hemoglobinuria Market, 2023-2033, USD (Million)
7.1. Market Overview
7.2. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
7.3.Paroxysmal Nocturnal Hemoglobinuria Market: By Region, 2023-2033, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
7.3.1.5. France
7.3.1.5.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)

8. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market, 2023-2033, USD (Million)
8.1. Market Overview
8.2. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
8.3.Paroxysmal Nocturnal Hemoglobinuria Market: By Region, 2023-2033, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
8.3.1.3. India
8.3.1.3.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)

9. Latin America Paroxysmal Nocturnal Hemoglobinuria Market, 2023-2033, USD (Million)
9.1. Market Overview
9.2. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
9.3.Paroxysmal Nocturnal Hemoglobinuria Market: By Region, 2023-2033, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)

10. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Market, 2023-2033, USD (Million)
10.1. Market Overview
10.2. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
10.3.Paroxysmal Nocturnal Hemoglobinuria Market: By Region, 2023-2033, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2023-2033, USD (Million)

11. Company Profile
11.1. Amgen, Inc.
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Achillion Pharmaceuticals
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Alexion Pharmaceutcials, Inc.
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Akari Therapeutics
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Apellis Pharmaceutcials, Inc.
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. CinnaGen
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. F.Hoffman-La Roche Ltd.
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Novartis AG
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Ra Pharmaceuticals
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Regeneron Pharmaceuticals
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives